Abstract
Immune checkpoint inhibitors (CPI) are the standard of care in patients (pts) failing platinum-based therapy for recurrent or metastatic head and neck cancer (r/m SCCHN). Here we explored the overall clinical impact of CPI in two real-world patient cohorts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
